Abcam, ab280122, Human NLRP3 knockout THP-1 cell lysate

Size: 1Kit
NLRP3 KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 58bp deletion in exon 2.
Key facts
Cell type:THP-1,
Species or organism:Human,
Tissue:Blood,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 58bp deletion in exon 2,
Disease:Acute Monocytic Leukemia

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-NLRP3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
NLRP3 also known as NALP3 or cryopyrin is a protein important for the inflammatory response. It is a component of the inflammasome which senses pathogenic microorganisms and stress. NLRP3 weighs around 118 kDa and is widely expressed in innate immune cells particularly macrophages and dendritic cells. Researchers often use techniques such as 'NLRP3 WB' (Western blot) and 'NLRP3 immunofluorescence' to study NLRP3 expression and localization.
Biological function summary
NLRP3 is central to the body’s defense mechanism by participating in forming the inflammasome complex which activates caspase-1. This activation leads to the cleavage of pro-inflammatory cytokines like IL-1β and IL-18 into their active forms. NLRP3's function is essential for mounting an effective immune response to infections and damage signals. It senses a range of stimuli including crystalline substances and cellular stress triggering an immune response. Its expression is tightly regulated to prevent excessive inflammation.
Pathways
The NLRP3 inflammasome is key in the innate immune response and inflammation pathways. It links cellular stress signals to inflammation through the activation of caspase-1 which is important for the IL-1 signaling pathway. NLRP3 interacts with other proteins like ASC (apoptosis-associated speck-like protein containing a CARD) to form the inflammasome complex which is a core part of the inflammatory signaling pathways and links innate and adaptive immunity.
NLRP3 has a significant role in inflammatory diseases and is linked to conditions like cryopyrin-associated periodic syndromes (CAPS) and gout. Mutations or dysregulation of NLRP3 lead to hyperactivation resulting in autoimmune and autoinflammatory conditions. NLRP3's interaction with IL-1 contributes to the excessive inflammatory response seen in these disorders. Understanding NLRP3's function in these pathways can inform therapeutic approaches targeting chronic inflammatory diseases.